On November 12, 2025 Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, reported a partnership for process transfer and cGMP manufacturing of HGI627, a novel therapy targeting pediatric liver cancer (hepatoblastoma).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Humane Genomics uses its proprietary synthetic RNA virus platform to rapidly design and engineer RNA viruses with precise anti-cancer capabilities. Through a two-factor selectivity mechanism, these therapies infect and replicate only in targeted cancer cells, leaving healthy tissue unharmed. The company’s platform powers a growing pipeline of next-generation viral therapies across multiple cancer types, including their lead candidate, HGI627.
Under this collaboration, Genezen will perform technology transfer, process development, and cGMP manufacturing of the VSV-based HGI627 therapy.
"Genezen is excited to partner with Humane Genomics on this novel cancer treatment and provide our best-in-class manufacturing expertise to bring this critical therapy to life for pediatric patients," said Steve Favaloro, chairman and chief executive officer of Genezen. "This partnership reinforces our commitment to supporting innovators at every stage of development and highlights the deep technical expertise and commitment to patients of the Genezen team."
Peter Weijmarshausen, co-founder and chief executive officer of Humane Genomics, added, "We are thrilled to partner with Genezen. Their experienced, dynamic team and state-of-the-art facilities make them a perfect match to turn our groundbreaking science into real therapies for patients."
(Press release, Genezen, NOV 12, 2025, View Source [SID1234659854])